GL1X · GenesisL1 explorer

MolNFT v1 · #165966 · protein

Met tyrosine kinase inhibition enhances the antitumor efficacy of an hgf antibody

6UBW · Hepatocyte growth factor receptor: “Met tyrosine kinase inhibition enhances the antitumor efficacy of an hgf antibody”. X-ray diffraction, 2 ligands (84S, CL), 2 pockets (best druggability 0.61). MolNFT v1 #165966 on GenesisL1: 3D…

PDB
6UBW
Type
protein
Length
296 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Hepatocyte growth factor receptor
EC
2.7.10.1
UniProt
P08581
Ligands
84S, CL
Pockets
2 · best druggability 0.61

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHepatocyte growth factor receptor (EC 2.7.10.1)protein29639% helix, 17% strandP08581

Ligands and binding sites

  • 84S · N-(6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2, 4]triazolo[4,3-a]pyridin-3-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide · ligand · chains A
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11980.610.822884S
21920.450.7423empty

Compared structures

  • 6UBW · MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.